Title of article
Angiogenesis inhibitor DC101 delays growth of intracerebral glioblastoma but induces morbidity when combined with irradiation
Author/Authors
Verhoeff، نويسنده , , Joost J.C. and Stalpers، نويسنده , , Lukas J.A. and Van Noorden، نويسنده , , Cornelis J.F. and Troost، نويسنده , , Dirk and Ramkema، نويسنده , , Marja D. and van Bree، نويسنده , , Chris and Song، نويسنده , , Ji-Ying and Donker، نويسنده , , Mila and Chekenya، نويسنده , , Martha and Vandertop، نويسنده , , W. Peter and Richel، نويسنده , , Dick J. and van Furth، نويسنده , , Wouter R.، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2009
Pages
7
From page
39
To page
45
Abstract
The combination of irradiation with angiogenic inhibition is increasingly being investigated for treatment of glioblastoma multiforme (GBM). We investigated whether vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitor DC101 affects morbidity and tumor growth in irradiated and non-irradiated intracerebral GBM-bearing mice, controlled with sham treatments. End-points were toxicity, morbidity and histology. Irradiation either or not combined, reduced tumor size strongly, whereas DC101 mono-treatment reduced tumor size by 64%. Irradiation delayed morbidity from 5.8 weeks in sham-treated mice to 10.3 weeks. Morbidity after combined treatment occurred after 5.9 weeks. Treatment with angiogenesis inhibitor DC101 delays tumor growth but it induces morbidity, by itself or combined with irradiation.
Keywords
Intracranial , Glioma , radiotherapy , Nude mouse , Angiogenesis inhibition
Journal title
Cancer Letters
Serial Year
2009
Journal title
Cancer Letters
Record number
1817876
Link To Document